Literature DB >> 8186299

Constitutive expression of chimeric neo-Rev response element transcripts suppresses HIV-1 replication in human CD4+ T lymphocytes.

D Bevec1, B Volc-Platzer, K Zimmermann, M Dobrovnik, J Hauber, G Veres, E Böhnlein.   

Abstract

We have previously reported that chimeric neomycin phosphotransferase (neo)-Rev response element (RRE) transcripts suppress the function of the human immunodeficiency virus type 1 (HIV-1) Rev trans-activator protein in HeLa cells. In an extension of these experiments, human CD4+ CEM cells (G418-resistant cell populations and clonal isolates) stably expressing chimeric neo-RRE genes (2, 3, or 6 RRE copies) were generated using retroviral-mediated gene transfer. The transduced CEM clones were infected with the HIV-1 HTLVIIIB isolate and the following three phenotypes were observed: (i) the transduced CEM cells were readily infected with HIV-1 indistinguishable from the control CEM cells; (ii) the appearance of HIV-1 replication markers was significantly delayed; (iii) no signs of HIV-1 replication were detectable although proviral HIV-1 DNA sequences could be detected in these cells. Furthermore, HIV antigen expression was limited in neo-resistant CEM cell populations inoculated with the HIV-1 HTLVIIIB isolate. Only 10% of the CEM-pX17-3xRRE cells and 20% of the CEM-pX17-2xRRE cells displayed HIV-1 antigens 43 days after challenge and had retained CD4 surface expression on 47% and 64% of the cells, respectively. In sharp contrast, 80% of the CEM-pX17 or the CEM-pX17-6xRRE cells expressed HIV-1 antigens but no CD4 antigens were detectable in these cultures. These results clearly indicate that RRE decoys could be developed into an effective somatic gene therapy approach against HIV-1 induced acquired immunodeficiency syndrome (AIDS).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8186299     DOI: 10.1089/hum.1994.5.2-193

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  10 in total

Review 1.  Gene therapy for HIV.

Authors:  A M Lever
Journal:  Sex Transm Infect       Date:  2001-04       Impact factor: 3.519

2.  Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter.

Authors:  J D Thompson; D F Ayers; T A Malmstrom; T L McKenzie; L Ganousis; B M Chowrira; L Couture; D T Stinchcomb
Journal:  Nucleic Acids Res       Date:  1995-06-25       Impact factor: 16.971

3.  Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.

Authors:  S W Lee; H F Gallardo; E Gilboa; C Smith
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

4.  Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells.

Authors:  A A Bukovsky; J P Song; L Naldini
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhibits viral replication in human CD4+ lymphocytes.

Authors:  G Veres; S Escaich; J Baker; C Barske; C Kalfoglou; H Ilves; H Kaneshima; E Böhnlein
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

6.  Cell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory gene.

Authors:  U Ranga; C Woffendin; Z Y Yang; L Xu; S Verma; D R Littman; G J Nabel
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

7.  Functional analysis of the human immunodeficiency virus type 1 Rev protein oligomerization interface.

Authors:  S L Thomas; M Oft; H Jaksche; G Casari; P Heger; M Dobrovnik; D Bevec; J Hauber
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection.

Authors:  M A Biasolo; A Radaelli; L Del Pup; E Franchin; C De Giuli-Morghen; G Palu
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication.

Authors:  S F Ding; J Noronha; S Joshi
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

Review 10.  Antisense inhibition of virus infections.

Authors:  R E Kilkuskie; A K Field
Journal:  Adv Pharmacol       Date:  1997
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.